secwatch.observer — SEC 8-K summary
======================================

Issuer:     BALCHEM CORP (BCPC)
CIK:        0000009326
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001628280-24-033055
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)
-------------------------------------------------------------------------------

- GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
- Record adjusted EBITDA $62.3M (+5.0% YoY); cash from ops $45.0M; free cash flow $38.4M.
- Human Nutrition & Health and Specialty Products segments post strong sales and earnings growth.
- Launched Optifolin+ patented choline-enriched folate ingredient on May 20, 2024.
- Repaid $35M revolving debt; net debt $202.8M; leverage ratio 0.9x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/9326/000162828024033055/0001628280-24-033055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/9326/000162828024033055/bcpc-20240726.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer